Elective partial nephrectomy is equivalent to radical nephrectomy in patients with clinical T1 renal cell carcinoma: results of a retrospective, comparative, multi‐institutional study
Study Type – Therapy (cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Few studies supported the expanded indications for nephron‐sparing surgery (NSS) in selected patients with 4.1 cm renal tumours in the size range (T1b). However, all these comparative st...
Saved in:
Published in | BJU international Vol. 109; no. 7; pp. 1013 - 1018 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
01.04.2012
Wiley-Blackwell Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
ISSN | 1464-4096 1464-410X 1464-410X |
DOI | 10.1111/j.1464-410X.2011.10431.x |
Cover
Loading…
Abstract | Study Type – Therapy (cohort)
Level of Evidence 2b
What's known on the subject? and What does the study add?
Few studies supported the expanded indications for nephron‐sparing surgery (NSS) in selected patients with 4.1 cm renal tumours in the size range (T1b). However, all these comparative studies included both imperative and elective partial nephrectomy and patient selection for analysis was based on pathological stage (pT1) and not on clinical stage (cT1).
Patients with clinically organ‐confined RCC (cT1) who are candidates for elective PN have a limited risk of clinical understaging. NSS is not associated with an increased risk of recurrence and cancer‐specific mortality both in cT1a and cT1b tumours
OBJECTIVE
•
To compare the oncological outcomes of patients who underwent elective partial nephrectomy (PN) or radical nephrectomy (RN) for clinically organ‐confined renal masses ≤7 cm in size (cT1).
PATIENTS AND METHODS
•
The records of 3480 patients with cT1N0M0 disease were extracted from a multi‐institutional database and analyzed retrospectively.
RESULTS
•
In patients who underwent PN, the risk of clinical understaging was 3.2% in cT1a cases and 10.6% in cT1b cases.
•
With regard to the cT1a patients, the 5‐ and 10‐year cancer‐specific survival (CSS) estimates were 94.7% and 90.4%, respectively, after RN and 96.1% and 94.9%, respectively, after PN (log‐rank test: P = 0.01).
•
With regard to cT1b patients, the 5‐year CSS probabilities were 92.6% after RN and 90% after PN, respectively (log‐rank test: P = 0.89).
•
Surgical treatment failed to be an independent predictor of CSS on multivariable analysis, both for cT1a and cT1b patients.
•
Interestingly, PN was oncologically equivalent to RN also in patients with pT3a tumours (log‐rank test: P = 0.91).
CONCLUSIONS
•
Elective PN is not associated with an increased risk of recurrence and cancer‐specific mortality in both cT1a and cT1b tumours.
•
Data from the present study strongly support the use of partial nephrectomy in patients with clinically T1 tumours, according to the current recommendations of the international guidelines. |
---|---|
AbstractList | To compare the oncological outcomes of patients who underwent elective partial nephrectomy (PN) or radical nephrectomy (RN) for clinically organ-confined renal masses ≤7 cm in size (cT1).
The records of 3480 patients with cT1N0M0 disease were extracted from a multi-institutional database and analyzed retrospectively.
In patients who underwent PN, the risk of clinical understaging was 3.2% in cT1a cases and 10.6% in cT1b cases. With regard to the cT1a patients, the 5- and 10-year cancer-specific survival (CSS) estimates were 94.7% and 90.4%, respectively, after RN and 96.1% and 94.9%, respectively, after PN (log-rank test: P = 0.01). With regard to cT1b patients, the 5-year CSS probabilities were 92.6% after RN and 90% after PN, respectively (log-rank test: P = 0.89). Surgical treatment failed to be an independent predictor of CSS on multivariable analysis, both for cT1a and cT1b patients. Interestingly, PN was oncologically equivalent to RN also in patients with pT3a tumours (log-rank test: P = 0.91).
Elective PN is not associated with an increased risk of recurrence and cancer-specific mortality in both cT1a and cT1b tumours. Data from the present study strongly support the use of partial nephrectomy in patients with clinically T1 tumours, according to the current recommendations of the international guidelines. Study Type – Therapy (cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Few studies supported the expanded indications for nephron‐sparing surgery (NSS) in selected patients with 4.1 cm renal tumours in the size range (T1b). However, all these comparative studies included both imperative and elective partial nephrectomy and patient selection for analysis was based on pathological stage (pT1) and not on clinical stage (cT1). Patients with clinically organ‐confined RCC (cT1) who are candidates for elective PN have a limited risk of clinical understaging. NSS is not associated with an increased risk of recurrence and cancer‐specific mortality both in cT1a and cT1b tumours OBJECTIVE • To compare the oncological outcomes of patients who underwent elective partial nephrectomy (PN) or radical nephrectomy (RN) for clinically organ‐confined renal masses ≤7 cm in size (cT1). PATIENTS AND METHODS • The records of 3480 patients with cT1N0M0 disease were extracted from a multi‐institutional database and analyzed retrospectively. RESULTS • In patients who underwent PN, the risk of clinical understaging was 3.2% in cT1a cases and 10.6% in cT1b cases. • With regard to the cT1a patients, the 5‐ and 10‐year cancer‐specific survival (CSS) estimates were 94.7% and 90.4%, respectively, after RN and 96.1% and 94.9%, respectively, after PN (log‐rank test: P = 0.01). • With regard to cT1b patients, the 5‐year CSS probabilities were 92.6% after RN and 90% after PN, respectively (log‐rank test: P = 0.89). • Surgical treatment failed to be an independent predictor of CSS on multivariable analysis, both for cT1a and cT1b patients. • Interestingly, PN was oncologically equivalent to RN also in patients with pT3a tumours (log‐rank test: P = 0.91). CONCLUSIONS • Elective PN is not associated with an increased risk of recurrence and cancer‐specific mortality in both cT1a and cT1b tumours. • Data from the present study strongly support the use of partial nephrectomy in patients with clinically T1 tumours, according to the current recommendations of the international guidelines. To compare the oncological outcomes of patients who underwent elective partial nephrectomy (PN) or radical nephrectomy (RN) for clinically organ-confined renal masses ≤7 cm in size (cT1).OBJECTIVETo compare the oncological outcomes of patients who underwent elective partial nephrectomy (PN) or radical nephrectomy (RN) for clinically organ-confined renal masses ≤7 cm in size (cT1).The records of 3480 patients with cT1N0M0 disease were extracted from a multi-institutional database and analyzed retrospectively.PATIENTS AND METHODSThe records of 3480 patients with cT1N0M0 disease were extracted from a multi-institutional database and analyzed retrospectively.In patients who underwent PN, the risk of clinical understaging was 3.2% in cT1a cases and 10.6% in cT1b cases. With regard to the cT1a patients, the 5- and 10-year cancer-specific survival (CSS) estimates were 94.7% and 90.4%, respectively, after RN and 96.1% and 94.9%, respectively, after PN (log-rank test: P = 0.01). With regard to cT1b patients, the 5-year CSS probabilities were 92.6% after RN and 90% after PN, respectively (log-rank test: P = 0.89). Surgical treatment failed to be an independent predictor of CSS on multivariable analysis, both for cT1a and cT1b patients. Interestingly, PN was oncologically equivalent to RN also in patients with pT3a tumours (log-rank test: P = 0.91).RESULTSIn patients who underwent PN, the risk of clinical understaging was 3.2% in cT1a cases and 10.6% in cT1b cases. With regard to the cT1a patients, the 5- and 10-year cancer-specific survival (CSS) estimates were 94.7% and 90.4%, respectively, after RN and 96.1% and 94.9%, respectively, after PN (log-rank test: P = 0.01). With regard to cT1b patients, the 5-year CSS probabilities were 92.6% after RN and 90% after PN, respectively (log-rank test: P = 0.89). Surgical treatment failed to be an independent predictor of CSS on multivariable analysis, both for cT1a and cT1b patients. Interestingly, PN was oncologically equivalent to RN also in patients with pT3a tumours (log-rank test: P = 0.91).Elective PN is not associated with an increased risk of recurrence and cancer-specific mortality in both cT1a and cT1b tumours. Data from the present study strongly support the use of partial nephrectomy in patients with clinically T1 tumours, according to the current recommendations of the international guidelines.CONCLUSIONSElective PN is not associated with an increased risk of recurrence and cancer-specific mortality in both cT1a and cT1b tumours. Data from the present study strongly support the use of partial nephrectomy in patients with clinically T1 tumours, according to the current recommendations of the international guidelines. Study Type - Therapy (cohort) Level of Evidence2b What's known on the subject? and What does the study add? Few studies supported the expanded indications for nephron-sparing surgery (NSS) in selected patients with 4.1cm renal tumours in the size range (T1b). However, all these comparative studies included both imperative and elective partial nephrectomy and patient selection for analysis was based on pathological stage (pT1) and not on clinical stage (cT1). Patients with clinically organ-confined RCC (cT1) who are candidates for elective PN have a limited risk of clinical understaging. NSS is not associated with an increased risk of recurrence and cancer-specific mortality both in cT1a and cT1b tumours OBJECTIVE * To compare the oncological outcomes of patients who underwent elective partial nephrectomy (PN) or radical nephrectomy (RN) for clinically organ-confined renal masses ≤7cm in size (cT1). PATIENTS AND METHODS * The records of 3480 patients with cT1N0M0 disease were extracted from a multi-institutional database and analyzed retrospectively. RESULTS * In patients who underwent PN, the risk of clinical understaging was 3.2% in cT1a cases and 10.6% in cT1b cases. * With regard to the cT1a patients, the 5- and 10-year cancer-specific survival (CSS) estimates were 94.7% and 90.4%, respectively, after RN and 96.1% and 94.9%, respectively, after PN (log-rank test: P=0.01). * With regard to cT1b patients, the 5-year CSS probabilities were 92.6% after RN and 90% after PN, respectively (log-rank test: P=0.89). * Surgical treatment failed to be an independent predictor of CSS on multivariable analysis, both for cT1a and cT1b patients. * Interestingly, PN was oncologically equivalent to RN also in patients with pT3a tumours (log-rank test: P=0.91). CONCLUSIONS * Elective PN is not associated with an increased risk of recurrence and cancer-specific mortality in both cT1a and cT1b tumours. * Data from the present study strongly support the use of partial nephrectomy in patients with clinically T1 tumours, according to the current recommendations of the international guidelines. [PUBLICATION ABSTRACT] |
Author | Simonato, Alchiede Cunico, Sergio Cosciani Zattoni, Filiberto Ficarra, Vincenzo Corti, Serena Novara, Giacomo Minervini, Andrea Martorana, Giuseppe Carini, Marco Bertini, Roberto Siracusano, Salvatore Mirone, Vincenzo Simeone, Claudio Carmignani, Giorgio Antonelli, Alessandro Longo, Nicola Serni, Sergio Volpe, Alessandro |
Author_xml | – sequence: 1 givenname: Alessandro surname: Antonelli fullname: Antonelli, Alessandro – sequence: 2 givenname: Vincenzo surname: Ficarra fullname: Ficarra, Vincenzo – sequence: 3 givenname: Roberto surname: Bertini fullname: Bertini, Roberto – sequence: 4 givenname: Marco surname: Carini fullname: Carini, Marco – sequence: 5 givenname: Giorgio surname: Carmignani fullname: Carmignani, Giorgio – sequence: 6 givenname: Serena surname: Corti fullname: Corti, Serena – sequence: 7 givenname: Nicola surname: Longo fullname: Longo, Nicola – sequence: 8 givenname: Giuseppe surname: Martorana fullname: Martorana, Giuseppe – sequence: 9 givenname: Andrea surname: Minervini fullname: Minervini, Andrea – sequence: 10 givenname: Vincenzo surname: Mirone fullname: Mirone, Vincenzo – sequence: 11 givenname: Giacomo surname: Novara fullname: Novara, Giacomo – sequence: 12 givenname: Sergio surname: Serni fullname: Serni, Sergio – sequence: 13 givenname: Claudio surname: Simeone fullname: Simeone, Claudio – sequence: 14 givenname: Alchiede surname: Simonato fullname: Simonato, Alchiede – sequence: 15 givenname: Salvatore surname: Siracusano fullname: Siracusano, Salvatore – sequence: 16 givenname: Alessandro surname: Volpe fullname: Volpe, Alessandro – sequence: 17 givenname: Filiberto surname: Zattoni fullname: Zattoni, Filiberto – sequence: 18 givenname: Sergio Cosciani surname: Cunico fullname: Cunico, Sergio Cosciani |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25647087$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21883829$$D View this record in MEDLINE/PubMed |
BookMark | eNqVks1u1DAQxy1URD_gFZAlhLiwwY6dxOGABFX5UiUurcTNmvU6qleJvbWdtnvjEXgdXocnYbK7LdKewAd7PP7NeDz-H5MDH7wlhHJWcBxvlgWXtZxJzr4XJeO84EwKXtw9IkcPBwf3NmvrQ3Kc0pIxdNTVE3JYcqWEKtsj8uustya7G0tXELODnnq7uoroC8OaukTt9ehuoLc-0xxohIUz-5DH2OyQSPTW5Stqeuc31AWn0Xo0jO1xgmicDwO8RW8ae8RDRwE3OYa02pbxmpowYCmw3QyIud8_fjqfsstjdmFKl_K4WD8ljzvok322W0_I5cezi9PPs_Nvn76cvj-fGVk2fKZMVyomYdE1HVSCzaVqSwsWeMWFZKY2dcmaeS2EamXXAbCqxWPOreWVARAn5NU27yqG69GmrAeXpgeBt2FMui2VqFveSCRf7JHLMEYsOGkuKiEq2bIKqec7apwPdqFX0Q0Q1_r-TxB4uQMgYRe7CN649Jeratkw1SCntpzB9qVouweEMz3JRC_1pAA9qUFPMtEbmeg7DH23F2pchqm7OYLr_yPBrevt-p8v1h--Xm5M8Qfnudvw |
CODEN | BJINFO |
CitedBy_id | crossref_primary_10_1016_j_euo_2019_02_006 crossref_primary_10_1186_s40001_014_0058_4 crossref_primary_10_1016_j_urology_2018_12_020 crossref_primary_10_1097_MOU_0b013e3283551f84 crossref_primary_10_1186_s12894_022_01088_3 crossref_primary_10_1016_j_euf_2015_04_001 crossref_primary_10_1007_s11255_017_1525_y crossref_primary_10_1097_MOU_0b013e328363a5c0 crossref_primary_10_1007_s40477_019_00413_1 crossref_primary_10_1634_theoncologist_2016_0435 crossref_primary_10_1111_bju_13353 crossref_primary_10_1177_0300891619853392 crossref_primary_10_1016_j_juro_2014_07_112 crossref_primary_10_1016_j_juro_2017_03_145 crossref_primary_10_1007_s00261_023_04146_y crossref_primary_10_1016_j_eururo_2012_02_039 crossref_primary_10_1016_j_juro_2016_01_099 crossref_primary_10_1007_s00345_012_0943_9 crossref_primary_10_1177_03915603221140964 crossref_primary_10_3390_cancers15030909 crossref_primary_10_1111_iju_12204 crossref_primary_10_1148_radiol_13130221 crossref_primary_10_17650_2070_9781_2023_24_3_66_74 crossref_primary_10_1007_s00345_013_1136_x crossref_primary_10_1016_j_eururo_2014_09_027 crossref_primary_10_1111_iju_12603 crossref_primary_10_1016_j_ajur_2019_11_004 crossref_primary_10_1111_bju_13888 crossref_primary_10_1590_s1677_5538_ibju_2020_0930 crossref_primary_10_1016_j_ijsu_2016_05_031 crossref_primary_10_1002_cam4_2993 crossref_primary_10_1016_j_clgc_2020_06_007 crossref_primary_10_1007_s00464_015_4382_8 crossref_primary_10_1007_s00270_012_0470_5 crossref_primary_10_3233_KCA_230001 crossref_primary_10_1089_end_2014_0517 crossref_primary_10_1097_MD_0000000000040721 crossref_primary_10_1148_radiol_2020200149 crossref_primary_10_1016_j_acra_2024_08_007 crossref_primary_10_1016_j_suronc_2016_09_001 crossref_primary_10_1177_107327481302000310 crossref_primary_10_1111_iju_13009 crossref_primary_10_1002_14651858_CD012045_pub2 crossref_primary_10_1016_j_ijsu_2016_03_038 crossref_primary_10_1016_j_juro_2016_04_081 crossref_primary_10_1097_MOU_0b013e32835ddab6 crossref_primary_10_1186_s12894_019_0480_6 crossref_primary_10_1111_bju_12204 crossref_primary_10_24060_2076_3093_2024_14_1_13_19 crossref_primary_10_1159_000443672 crossref_primary_10_1002_jbm_b_34637 crossref_primary_10_1089_end_2013_0197 crossref_primary_10_1016_j_ejso_2014_12_001 crossref_primary_10_1186_s12957_024_03302_y crossref_primary_10_1089_end_2015_0411 crossref_primary_10_1089_end_2020_0314 crossref_primary_10_1586_erd_12_94 crossref_primary_10_1016_j_urolonc_2016_12_011 crossref_primary_10_1111_bju_13627 crossref_primary_10_1186_1471_2407_14_372 crossref_primary_10_1016_j_eururo_2016_08_060 crossref_primary_10_1200_JCO_2016_69_9645 crossref_primary_10_1016_j_urology_2015_05_013 crossref_primary_10_1111_bju_12570 crossref_primary_10_1245_s10434_017_5831_5 crossref_primary_10_1007_s00345_016_1923_2 crossref_primary_10_1002_jso_24695 crossref_primary_10_1007_s12325_013_0061_0 crossref_primary_10_1111_iju_13544 crossref_primary_10_1016_j_urology_2015_08_049 |
Cites_doi | 10.1097/01.ju.0000124846.37299.5e 10.1016/j.eururo.2010.08.001 10.1016/j.eururo.2007.11.007 10.1016/j.eururo.2006.11.013 10.1097/01.ju.0000135837.64840.55 10.1007/978-1-4757-3656-4 10.1016/j.urology.2008.08.492 10.1016/j.eururo.2009.07.040 10.1097/00000478-198210000-00007 10.1016/j.eururo.2010.04.033 10.1016/j.eururo.2010.06.032 10.1111/j.1464-410X.2006.06060.x 10.1016/j.eururo.2009.10.019 10.1097/01.ju.0000113274.40885.db 10.1016/j.ejso.2008.07.008 10.1016/S1470-2045(06)70803-8 10.1016/S0022-5347(17)68620-8 10.1016/j.eururo.2009.10.023 10.1016/j.juro.2009.05.035 10.1200/JCO.1999.17.9.2868 10.1016/S0022-5347(17)62331-0 10.1016/S0022-5347(05)67793-2 |
ContentType | Journal Article |
Copyright | 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL 2015 INIST-CNRS 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL. |
Copyright_xml | – notice: 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL – notice: 2015 INIST-CNRS – notice: 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL. |
CorporateAuthor | members of the SATURN Project – LUNA Foundation members of the SATURN Project - LUNA Foundation |
CorporateAuthor_xml | – name: members of the SATURN Project – LUNA Foundation – name: members of the SATURN Project - LUNA Foundation |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7QP 7X8 |
DOI | 10.1111/j.1464-410X.2011.10431.x |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic Calcium & Calcified Tissue Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1464-410X |
EndPage | 1018 |
ExternalDocumentID | 2975476721 21883829 25647087 10_1111_j_1464_410X_2011_10431_x BJU10431 |
Genre | article Multicenter Study Journal Article Comparative Study |
GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACUHS ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EBC EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FUBAC G-S G.N GODZA H.X HF~ HGLYW HZI HZ~ IHE IX1 J0M J5H K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 R.K RJQFR ROL RX1 SUPJJ SV3 TEORI TUS UB1 V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 YFH ZGI ZXP ~IA ~WT AAYXX AEYWJ AGHNM AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY IQODW CGR CUY CVF ECM EIF NPM 7QP 1OB 7X8 |
ID | FETCH-LOGICAL-c4271-8cf2804adf7fa530b4892eaea151340c6c6207b633894ffaa059eae11ee15caa3 |
IEDL.DBID | DR2 |
ISSN | 1464-4096 1464-410X |
IngestDate | Tue Aug 05 10:32:57 EDT 2025 Fri Jul 25 06:36:47 EDT 2025 Thu Apr 03 07:07:35 EDT 2025 Mon Jul 21 09:14:16 EDT 2025 Tue Jul 01 03:49:52 EDT 2025 Thu Apr 24 23:44:10 EDT 2025 Wed Jan 22 16:20:39 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Keywords | Kidney disease Human Nephrology Urinary system disease Carcinoma clinical staging radical nephrectomy Staging Stage classification renal cancer Malignant tumor partial nephrectomy Retrospective Urology Conservative surgery Treatment nephron-sparing surgery Nephrectomy Partial Kidney cancer Nephron Grawitz tumor Comparative study Cancer |
Language | English |
License | CC BY 4.0 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4271-8cf2804adf7fa530b4892eaea151340c6c6207b633894ffaa059eae11ee15caa3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 content type line 23 |
PMID | 21883829 |
PQID | 1353354905 |
PQPubID | 1026371 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_928369174 proquest_journals_1353354905 pubmed_primary_21883829 pascalfrancis_primary_25647087 crossref_primary_10_1111_j_1464_410X_2011_10431_x crossref_citationtrail_10_1111_j_1464_410X_2011_10431_x wiley_primary_10_1111_j_1464_410X_2011_10431_x_BJU10431 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | April 2012 |
PublicationDateYYYYMMDD | 2012-04-01 |
PublicationDate_xml | – month: 04 year: 2012 text: April 2012 |
PublicationDecade | 2010 |
PublicationPlace | Oxford, UK |
PublicationPlace_xml | – name: Oxford, UK – name: Oxford – name: England – name: Edgecliff |
PublicationTitle | BJU international |
PublicationTitleAlternate | BJU Int |
PublicationYear | 2012 |
Publisher | Blackwell Publishing Ltd Wiley-Blackwell Wiley Subscription Services, Inc |
Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley-Blackwell – name: Wiley Subscription Services, Inc |
References | 2009; 56 2009; 35 2006; 97 2009; 73 2010; 58 2010; 57 1950; 64 2009; 182 1999; 17 1982; 6 2004; 172 2004; 171 2006; 7 2009 2000; 163 2004 2007; 51 2008; 53 2002 1969; 101 e_1_2_7_5_2 e_1_2_7_4_2 e_1_2_7_3_2 e_1_2_7_2_2 e_1_2_7_9_2 Greene FL (e_1_2_7_16_2) 2002 e_1_2_7_8_2 e_1_2_7_7_2 e_1_2_7_6_2 e_1_2_7_19_2 e_1_2_7_18_2 e_1_2_7_15_2 e_1_2_7_14_2 e_1_2_7_25_2 e_1_2_7_13_2 e_1_2_7_24_2 e_1_2_7_12_2 e_1_2_7_23_2 e_1_2_7_11_2 e_1_2_7_22_2 e_1_2_7_10_2 e_1_2_7_21_2 e_1_2_7_20_2 Eble JN (e_1_2_7_17_2) 2004 |
References_xml | – volume: 56 start-page: 786 year: 2009 end-page: 93 article-title: Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron‐sparing surgery publication-title: Eur Urol – year: 2009 – volume: 97 start-page: 939 year: 2006 end-page: 45 article-title: Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4–7 cm publication-title: BJU Int – volume: 57 start-page: 223 year: 2010 end-page: 32 article-title: A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer publication-title: Eur Urol – volume: 171 start-page: 2181 year: 2004 end-page: 5 article-title: Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience publication-title: J Urol – volume: 17 start-page: 2868 year: 1999 end-page: 75 article-title: Efficacy of nephron‐sparing surgery for renal cell carcinoma: analysis based on the new 1997 tumor‐node‐metastasis staging system publication-title: J Clin Oncol – volume: 58 start-page: 398 year: 2010 end-page: 406 article-title: EAU guidelines on renal cell carcinoma: the 2010 update publication-title: Eur Urol – volume: 58 start-page: 655 year: 2010 end-page: 68 article-title: Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors publication-title: Eur Urol – year: 2002 – volume: 35 start-page: 636 year: 2009 end-page: 42 article-title: The use of partial nephrectomy in european tertiary care centers publication-title: Eur J Surg Oncol – volume: 182 start-page: 844 year: 2009 end-page: 53 article-title: The RENAL nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth publication-title: J Urol – year: 2004 – volume: 64 start-page: 200 year: 1950 end-page: 8 article-title: Indications for conservative surgery in certain renal tumors: a study based on the growth pattern of the cell carcinoma publication-title: J Urol – volume: 172 start-page: 858 year: 2004 end-page: 62 article-title: Multi‐institutional validation of a symptom based classification for renal cell carcinoma publication-title: J Urol – volume: 51 start-page: 1606 year: 2007 end-page: 15 article-title: A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron‐sparing surgery and radical nephrectomy for low‐stage renal cell carcinoma publication-title: Eur Urol – volume: 53 start-page: 803 year: 2008 end-page: 9 article-title: Nephron‐sparing surgery versus radical nephrectomy in the treatment of intracapsular renal cell carcinoma up to 7 cm publication-title: Eur Urol – volume: 73 start-page: 1300 year: 2009 end-page: 5 article-title: Partial versus radical nephrectomy in patients with adverse clinical or pathologic characteristics publication-title: Urology – volume: 171 start-page: 1066 year: 2004 end-page: 70 article-title: Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy publication-title: J Urol – volume: 6 start-page: 655 year: 1982 end-page: 63 article-title: Prognostic significance of morphologic parameters in renal cell carcinoma publication-title: Am J Surg Pathol – volume: 163 start-page: 730 year: 2000 end-page: 6 article-title: Surgical management of renal tumors 4 cm. or less in a contemporary cohort publication-title: J Urol – volume: 7 start-page: 735 year: 2006 end-page: 40 article-title: Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study publication-title: Lancet Oncol – volume: 58 start-page: 293 year: 2010 end-page: 8 article-title: Partial nephrectomy is associated with improved overall survival compared to radical nephrectomy in patients with unanticiapted benign renal tumours publication-title: Eur Urol – volume: 101 start-page: 297 year: 1969 end-page: 301 article-title: The results of radical nephrectomy for renal cell carcinoma publication-title: J Urol – volume: 57 start-page: 214 year: 2010 end-page: 22 article-title: The expanding role of partial nephrectomy: a critical analysis of indications, results and complications publication-title: Eur Urol – ident: e_1_2_7_11_2 doi: 10.1097/01.ju.0000124846.37299.5e – ident: e_1_2_7_23_2 doi: 10.1016/j.eururo.2010.08.001 – ident: e_1_2_7_14_2 doi: 10.1016/j.eururo.2007.11.007 – ident: e_1_2_7_7_2 doi: 10.1016/j.eururo.2006.11.013 – ident: e_1_2_7_15_2 doi: 10.1097/01.ju.0000135837.64840.55 – volume-title: American Joint Committee on Cancer (AJCC) Staging Manual year: 2002 ident: e_1_2_7_16_2 doi: 10.1007/978-1-4757-3656-4 – ident: e_1_2_7_22_2 doi: 10.1016/j.urology.2008.08.492 – ident: e_1_2_7_25_2 doi: 10.1016/j.eururo.2009.07.040 – ident: e_1_2_7_18_2 doi: 10.1097/00000478-198210000-00007 – ident: e_1_2_7_5_2 doi: 10.1016/j.eururo.2010.04.033 – volume-title: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs year: 2004 ident: e_1_2_7_17_2 – ident: e_1_2_7_8_2 doi: 10.1016/j.eururo.2010.06.032 – ident: e_1_2_7_13_2 doi: 10.1111/j.1464-410X.2006.06060.x – ident: e_1_2_7_6_2 doi: 10.1016/j.eururo.2009.10.019 – ident: e_1_2_7_12_2 doi: 10.1097/01.ju.0000113274.40885.db – ident: e_1_2_7_21_2 doi: 10.1016/j.ejso.2008.07.008 – ident: e_1_2_7_4_2 doi: 10.1016/S1470-2045(06)70803-8 – ident: e_1_2_7_3_2 doi: 10.1016/S0022-5347(17)68620-8 – ident: e_1_2_7_10_2 doi: 10.1016/j.eururo.2009.10.023 – ident: e_1_2_7_9_2 – ident: e_1_2_7_24_2 doi: 10.1016/j.juro.2009.05.035 – ident: e_1_2_7_20_2 doi: 10.1200/JCO.1999.17.9.2868 – ident: e_1_2_7_2_2 doi: 10.1016/S0022-5347(17)62331-0 – ident: e_1_2_7_19_2 doi: 10.1016/S0022-5347(05)67793-2 |
SSID | ssj0014665 |
Score | 2.3312435 |
SecondaryResourceType | review_article |
Snippet | Study Type – Therapy (cohort)
Level of Evidence 2b
What's known on the subject? and What does the study add?
Few studies supported the expanded indications for... To compare the oncological outcomes of patients who underwent elective partial nephrectomy (PN) or radical nephrectomy (RN) for clinically organ-confined renal... Study Type - Therapy (cohort) Level of Evidence2b What's known on the subject? and What does the study add? Few studies supported the expanded indications for... |
SourceID | proquest pubmed pascalfrancis crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1013 |
SubjectTerms | Biological and medical sciences Cancer Carcinoma, Renal Cell - mortality Carcinoma, Renal Cell - pathology Carcinoma, Renal Cell - surgery clinical staging Elective Surgical Procedures Female Humans Kidney Neoplasms - mortality Kidney Neoplasms - pathology Kidney Neoplasms - surgery Kidneys Male Medical research Medical sciences Middle Aged Mortality Nephrectomy - methods Nephrology. Urinary tract diseases nephron‐sparing surgery partial nephrectomy radical nephrectomy renal cancer Survival Rate Tumors of the urinary system |
Title | Elective partial nephrectomy is equivalent to radical nephrectomy in patients with clinical T1 renal cell carcinoma: results of a retrospective, comparative, multi‐institutional study |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1464-410X.2011.10431.x https://www.ncbi.nlm.nih.gov/pubmed/21883829 https://www.proquest.com/docview/1353354905 https://www.proquest.com/docview/928369174 |
Volume | 109 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LatwwFBUli1IofT_cpkGLLuNBsmVZ011bEkIgXZQMzE7IGhmGTOzJ2Ia2q35Cf6e_0y_pvZLt4JBFKN35oSuPRkfSkXR1LiHvZWGZSe0qTq0VMTBiFRtmLTQ8zlcWYF0UuN5x9kWeLMTpMlv2_k94FiboQ4wLbtgyfH-NDdwUzc1GDtlztgxKnBx1YmbIJ9F1C_nR11FJCpL6qJLBBGj71Knn1owmI9XDrWngTytDtIvb6OiU3frh6fgxuRgKFrxSLmZdW8zsjxuaj_-n5E_Io57F0o8Bdk_JPVc9I_fP-n365-T30SZ0pHSL0ISklUPU2La-_E7XDXVX3RowDiMebWu6M363aJqoor3ma0NxsZgOZzjpOac7h5_HTQdqMRhSVV-aD_C06TaQvC6pgZt2Vw_nSA-pvVY5P6Tei_LPz1_r3lPCL4dSr7T7giyOj84_n8R9kIjYiiTnsbJlopgwqzIvTZayQqh54owzQGVSway0MmF5IWEqPhdlaQzwSXjNuXM8s8akL8leVVfuNaFSMelWiXLIylQmVcFSscqzMnHMSZdEJB8AoW2voI6BPDZ6MpMSGmtGY81oXzP6W0T4aLkNKiJ3sDmYYG40BJIqcqbyiOwPINR9x9NoDGOSwpyfZRGh42voMrBKTOXqrtFzoJQSpukiIq8Cdq_z5kqlKplDUT0C7_xr9afThb9888-Wb8kDeJ4Et6h9stfuOvcOGF9bHPi2_BcPW0s- |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dbtMwFLbQkAAJ8Q8LjOELLpfKThzH5Y6fTWWsu0Ct1DvLcR2pWpeUJpEGVzwCr8Pr8CQc20mmTLuYEHdtc45b19-xPx8fn4PQW55pomK9DGOtWQiMWISKaA2GR-lSA6yzzPo7pqd8MmfHi2TRlgOyd2F8foje4WYtw83X1sCtQ_qqlUP7lCx8Kk5qE8WMgFDetgW-bTmDT1_7XFIg6-pKeh0g7sOwnmtbGqxV9zeqgr8t9_UuriOkQ37rFqijh2jddc3HpZyNmjob6R9Xsj7-p74_Qg9aIovfe-Q9RrdM8QTdmbZH9U_R78O1n0vxxqITRAtjgaPr8vw7XlXYfGtWAHNY9HBd4q1yB0ZDoQK3aV8rbP3FuLvGiWcUb439envugLWth1SU5-odfFo1axAvc6zgTb0tu6ukB1hfJjo_wC6Q8s_PX6s2WMJ5RLFLtvsMzY8OZx8nYVsnItQsSmkodB4JwtQyT3OVxCRjYhwZZRSwmZgRzTWPSJpx2I2PWZ4rBZQSHlNqDE20UvFztFOUhdlFmAvCzTISxhIzkXCRkZgt0ySPDDHcRAFKO0RI3SZRt7U81nKwmWLSjoy0IyPdyMiLANFec-MTidxAZ38Aul4ReCpLiUgDtNehULZzTyVtJZMYtv0kCRDuH8OsYYdEFaZsKjkGVslhp84C9MKD97JtKkQsojF01UHwxr9Wfjieu5cv_1nzDbo7mU1P5Mnn0y-v0D2QiXyU1B7aqbeNeQ0EsM72nWH_BaBET1g |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQkSokxP9PoBQfODYrO3EcLzd-uiqFVgh1pb1ZjuNIq26TZZNILScegdfhdXgSxnaSKlUPFeK22cw4cfyN_dkezyD0hmeaqFjnYaw1C4ERi1ARrcHwKM01wDrL7HrH0TE_mLPDRbLo_J_sWRgfH2JYcLOW4fpra-DrvLhq5FA8JQsfiZPaODET4JO3GYeHWIL0bQglBbIuraTXAd4-9uq5tqTRUHV3rWr4aoVPd3EdHx3TWzc-ze6j075m3i3ldNI22UT_uBL08f9U_QG619FY_M7j7iG6ZcpHaPuo26h_jH7vr3xPitcWmyBaGgsb3VRnF3hZY_O9XQLIYcjDTYU3ym0XjYVK3AV9rbFdLcb9IU58QvHG2MfbXQesbTaksjpTb-Hful2BeFVgBRfNpuoPku5hfRnmfA87N8o_P38tO1cJtx6KXajdJ2g-2z_5cBB2WSJCzaKUhkIXkSBM5UVaqCQmGRPTyCijgMvEjGiueUTSjMNcfMqKQikglHCbUmNoopWKn6KtsirNc4S5INzkkTCWlomEi4zELE-TIjLEcBMFKO0BIXUXQt1m8ljJ0VSKSdsy0raMdC0jzwNEB821DyNyA53dEeYGRWCpLCUiDdBOD0LZ9Ty1tHlMYpj0kyRAeLgNfYZtElWaqq3lFDglh3k6C9Azj93LsqkQsYimUFWHwBu_rXx_OHc_X_yz5mu0_fXjTH75dPz5JboDIpF3kdpBW82mNa-A_TXZrjPrv42pThA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Elective+partial+nephrectomy+is+equivalent+to+radical+nephrectomy+in+patients+with+clinical+T1+renal+cell+carcinoma%3A+results+of+a+retrospective%2C+comparative%2C+multi-institutional+study&rft.jtitle=BJU+international&rft.au=Antonelli%2C+Alessandro&rft.au=Ficarra%2C+Vincenzo&rft.au=Bertini%2C+Roberto&rft.au=Carini%2C+Marco&rft.date=2012-04-01&rft.issn=1464-410X&rft.eissn=1464-410X&rft.volume=109&rft.issue=7&rft.spage=1013&rft_id=info:doi/10.1111%2Fj.1464-410X.2011.10431.x&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1464-4096&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1464-4096&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1464-4096&client=summon |